Scarica l'app Stockscreener
1.76
4.86%
-0.09
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
With financing closed, Scinai (SCNI) estimates runway to late 2027, subject to sales, collections and execution. - Stock Titan
Each depositary share represents 10,000 ordinary shares at RedHill Biopharma (RDHL). - Stock Titan
Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle - Stock Titan
If all warrants are exercised for cash, Can-Fite (CANF) could receive $8.31M as it registers shares for resale. - Stock Titan
Warrants on 7.6M CANF shares highlight dilution risk - Stock Titan
CANFCan-Fite Biopharma Ltd ADR Short Interest - Finviz
Repriced deal gives Can-Fite (CANF) $4M cash and 3.18M new ADS warrants - Stock Titan
CANF 6-K & SEC Filings - Yahoo Finance Australia
Which stocks are gapping on Wednesday? - ChartMill
Discover the top movers in Wednesday's pre-market session. - ChartMill
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - globenewswire.com
Can-Fite BioPharma (CANF) halves warrant price in cash-for-warrants deal - Stock Titan
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - markets.businessinsider.com
Can-Fite (CANF) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: The Stock Records a 0.60% Decrease on the DayFinal Results - careplusvn.com
Can-Fite (CANF) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: The Stock Records a 0.60% Decrease on the DayShort-Term Outlook - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionALMA Signal - careplusvn.com
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionETF Liquidity - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionDouble Bottom - siam.in
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionZero Lag EMA - www.dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionFear Greed Index - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionMACD Signal Stocks - www.dars.gov.et
Can-Fite (CANF) Range: Loses 0.29% to Close at $3.44 for the Current Session; Next Test: $3.27 and $3.61 Define the Nearby Reference Levels in the Current UpdateGap and Reverse - careplusvn.com
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - Sahm
Baidu, Inc. (BIDU) CEO logs 852,904 restricted share conversions and major Class B stake - Stock Titan
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewswire Inc.
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Hesai Group (NYSE: HSAI) enacts 1-for-8 share subdivision and updates ADS ratio - Stock Titan
Why is Can-Fite BioPharma stock climbing today? - Investing.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Wednesday's session: gap up and gap down stocks - ChartMill
Can Fite Biopharma stock surges 65% on pancreatic cancer data By Investing.com - Investing.com Nigeria
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
What's going on in today's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
Friday's after hours session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Top movers in Friday's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com Canada
RedHill closes $6M financing, with up to $13.4M more possible - Stock Titan
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Stock Price, Quote & Chart - ChartMill
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):